NCT06505746Completed
A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia
Adelphi Real World Metastatic Urothelial Cancer Disease Specific Programme: Study of Real-world Data to Evaluate Patient Characteristics, Treatment Pattern and Healthcare Resource Utilisation of Locally Advanced or Metastatic Urothelial Cancer (La/mUC) at First-line Setting Post Avelumab Reimbursement in South Korea and Saudi Arabia
Source: ClinicalTrials.gov · Last updated 24 Mar 2025
Brief summary (registry, in English)
Cancer in the bladder lining (urothelial cancer) can be treated in many ways. One way is to directly attack cancer cells. Enfortumab vedotin is a treatment that can do this. Another way is to help the body's immune system find and attack cancer cells. Avelumab is a treatment that can do this. Both treatments were recently approved in some countries. Doctors have standard clinical practice guidelines to help them treat people with cancer. This study is about collecting information on how adults with urothelial cancer are treated in standard clinical practice. The people in this study will have locally advanced or metastatic urothelial cancer. Locally advanced means the cancer has spread to tissue close by. Metastatic means the cancer has spread to other parts of the body. The goal of this study is to learn how people with urothelial cancer receive medical care in clinics in South Korea and Saudi Arabia. The main goals are to learn more about the people receiving treatments, and the treatments they receive. This study is about collecting information only. The individual's doctor decides on treatment, not the study sponsor (Astellas). Information will be collected from the people's medical records. This will include 12 months before treatment starts, and during treatment. Also, doctors will answer questions in interviews and surveys about how they care for people with urothelial cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 287 (actual)
- First submitted
- 11 Jul 2024
- Start date
- 29 Aug 2024
- Primary completion date
- 31 Jan 2025
- Lead sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Diseases
- Bladder cancer
- NCT number
- NCT06505746
What you commit to
- Study type: Observational
- Participants enrolled: 287
- From 29 Aug 2024 to the primary completion date, 31 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients participating in, or who have previously participated, in a clinical trial
Other
- Patients currently enrolled in a clinical trial
Who the study is looking for
- Physician sample:
- Medical oncologist or urologist (Medical oncologists only in Saudi Arabia. A minimum of 15 medical oncologists in South Korea, increased where possible, with the remaining sample consisting of urologists)
- Personally responsible for treatment and management of LA/mUC patients
- At least 50 percent of time spent in management of patients
- See a minimum of 4 LA/mUC patients per month
- Accept all survey rules and requirements
- Patient sample:
- Confirmed/physician assessed diagnosis of LA/mUC
- Patient is not currently enrolled in a clinical trial
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| KR00001 Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.